These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18521973)

  • 21. FDA clearance for ritonavir in children with AIDS.
    AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361797
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug interactions. Coming soon--a new formulation of Kaletra.
    TreatmentUpdate; 2006; 18(3):7. PubMed ID: 17209241
    [No Abstract]   [Full Text] [Related]  

  • 23. New anti-HIV drugs in development.
    Proj Inf Perspect; 1999 Sep; (28):4-8. PubMed ID: 11367365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA approves new dosing for amprenavir and ritonavir combination.
    AIDS Treat News; 2002 Mar; (378):6-7. PubMed ID: 11965920
    [No Abstract]   [Full Text] [Related]  

  • 25. Kaletra (ABT-378/r) approved.
    James JS
    AIDS Treat News; 2000 Sep; (351):2-3. PubMed ID: 12173550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CASTLE study showed similar efficacy.
    AIDS Patient Care STDS; 2008 Mar; 22(3):253. PubMed ID: 18348342
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination suppresses HIV RNA within the central nervous system.
    AIDS Patient Care STDS; 1998 Jan; 12(1):65. PubMed ID: 11361893
    [No Abstract]   [Full Text] [Related]  

  • 28. Combo approved for HIV treatment.
    Nurse Pract; 2004 Mar; 29(3):40. PubMed ID: 15052701
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
    L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
    AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
    Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosted saquinavir approved.
    AIDS Patient Care STDS; 2004 Mar; 18(3):183. PubMed ID: 15112642
    [No Abstract]   [Full Text] [Related]  

  • 32. Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy".
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):4. PubMed ID: 15717366
    [No Abstract]   [Full Text] [Related]  

  • 33. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
    Ray AS; Wright MR; Rhodes GR
    Clin Pharmacol Ther; 2008 Dec; 84(6):660; author reply 661. PubMed ID: 18615003
    [No Abstract]   [Full Text] [Related]  

  • 34. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
    Bénard A; Damond F; Campa P; Peytavin G; Descamps D; Lascoux-Combes C; Taieb A; Simon F; Autran B; Brun-Vézinet F; Chêne G; Matheron S;
    AIDS; 2009 Jun; 23(9):1171-3. PubMed ID: 19349850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
    Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
    Wilkins E
    J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir.
    TreatmentUpdate; 2004; 16(3):8. PubMed ID: 17216837
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-HIV agents. Monotherapy studies--points to consider.
    TreatmentUpdate; 2008 Jan; 20(1):3-4. PubMed ID: 18320692
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved tolerability and quality of life with the new lopinavir/ritonavir tablet formulation.
    Olmo M; Ferrer E; Curto J; Barragán P; Saumoy M; Perulero N; Podzamczer D
    J Infect; 2008 Dec; 57(6):503-5. PubMed ID: 18952298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.